Global Pharma Giants Race to Dominate Oncology: A Worldwide M&A Wave Reshapes Cancer Treatment
The world's largest pharmaceutical companies are deploying tens of billions of dollars to acquire oncology biotechs and secure regulatory approvals, transforming the global cancer drug market. From the United States to Europe and Asia, consolidation is accelerating as patent cliffs force Big Pharma to replenish pipelines through acquisition rather than internal discovery. The race to dominate next-generation cancer therapies — from antibody-drug conjugates to oral protein degraders — is now one
ViaNews Editorial Team•